| Promiscuity and Quantitative Contribution of UGT2B17 in Drug and Steroid Metabolism Determined by Experimental and Computational Approaches. | Promiscuity and Quantitative Contribution of UGT2B17 in Drug and Steroid Metabolism Determined by Experimental and Computational Approaches.
Ahire D, Mariasoosai C, Naji-Talakar S, Natesan S, Prasad B. | 01/29/2024 |
| A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome. | A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Wagner A, Rouleau M, Villeneuve L, Le T, Peltier C, Allain ÉP, Beaudoin C, Tremblay S, Courtier F, Nguyen Van Long F, Laverdière I, Lévesque É, Banerji V, Vanura K, Guillemette C., Free PMC Article | 05/19/2023 |
| Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer. | Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer.
Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C., Free PMC Article | 03/2/2023 |
| Genes ACOT1, GSTM1, SIGLEC14 and UGT2B17 are identified as highly absent genes in gastric cancer population. | Pangenomic analysis of Chinese gastric cancer.
Yu Y, Zhang Z, Dong X, Yang R, Duan Z, Xiang Z, Li J, Li G, Yan F, Xue H, Jiao D, Lu J, Lu H, Zhang W, Wei Y, Fan S, Li J, Jia J, Zhang J, Ji J, Liu P, Lu H, Zhao H, Chen S, Wei C, Chen H, Zhu Z., Free PMC Article | 10/21/2022 |
| Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells. | Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells.
Shafiee-Kermani F, Carney ST, Jima D, Utin UC, Farrar LB, Oputa MO, Hines MR, Kinyamu HK, Trotter KW, Archer TK, Hoyo C, Koller BH, Freedland SJ, Grant DJ., Free PMC Article | 01/15/2022 |
| Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro. | Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro.
Salhab H, Naughton DP, Barker J., Free PMC Article | 09/18/2021 |
| UGT2B17 modifies drug response in chronic lymphocytic leukaemia. | UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Allain EP, Rouleau M, Vanura K, Tremblay S, Vaillancourt J, Bat V, Caron P, Villeneuve L, Labriet A, Turcotte V, Le T, Shehata M, Schnabl S, Demirtas D, Hubmann R, Joly-Beauparlant C, Droit A, Jäger U, Staber PB, Lévesque E, Guillemette C., Free PMC Article | 02/20/2021 |
| Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. | Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C., Free PMC Article | 01/16/2021 |
| Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer. | Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H, Aristarco V, Gandini S, Gjerde J, Macis D, Guerrieri-Gonzaga A, Serrano D, Lazzeroni M, Rajasekaran A, Williard CV, Mellgren G, DeCensi A, Bonanni B. | 01/9/2021 |
| UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus. | UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus.
Lian X, Baranova A, Ngo J, Yu G, Cao H., Free PMC Article | 09/5/2020 |
| Help characterize the UGT2B17 level in various disease states. | Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.
Émond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, Brisson H, Lacombe L, Simonyan D, Caron P, Périgny M, Têtu B, Fallon JK, Klein K, Smith PC, Zanger UM, Guillemette C, Lévesque E. | 01/25/2020 |
| Exemestane is less detrimental to bone health than letrozole in postmenopausal women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though this finding requires independent validation. | Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL., Free PMC Article | 11/16/2019 |
| These data can be used to predict variability in the metabolism of UGT2B17 substrates. | Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B., Free PMC Article | 11/17/2018 |
| Clopidogrel carboxylic acid is metabolized mainly by UGT2B7 and UGT2B4 in the liver and by UGT2B17 in the small intestinal wall. | Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions( ).
Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT. | 10/20/2018 |
| UGT2B17 was deleted in 64% of children with lymphoblastic malignancy, but in 83% of children with non-lymphoblastic malignancy. UGT2B17 deletion polymorphism may improve the relapse-free rate in children with non-lymphoblastic malignancy. | Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S, Yuza Y, Kaneko T, Urashima M. | 10/7/2017 |
| Study provides the first evidence of null genotype involvement in UGT2B17 as a risk factor for benign prostatic hyperplasia. | Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M, Mirfakhraie R, Khani M, Rakhshan A, Azargashb E, Pouresmaeili F. | 10/7/2017 |
| the UGT2B15 and UGT2B17 enzymes are transcriptionally regulated by sex hormone signaling in ERalpha+ breast cancer cells and are highly expressed in a subset of primary breast cancers. | Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.
Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, Tilley WD, Mackenzie PI, Hickey TE. | 08/5/2017 |
| Chronic lymphocytic leukemia patients with high UGT2B17 and LPL expression have significantly reduced survival. | UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton LA, Mansouri L., Free PMC Article | 01/14/2017 |
| UGT2B17 contributes to the in-vitro glucuronidation of arctigenin in liver/intestinal microsomes. | Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin.
Xin H, Xia YL, Hou J, Wang P, He W, Yang L, Ge GB, Xu W. | 11/5/2016 |
| GC-C-IRMS analysis sensitive to testosterone doping independent of UGT2B17 genotype. | Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism.
Strahm E, Mullen JE, Gårevik N, Ericsson M, Schulze JJ, Rane A, Ekström L. | 10/1/2016 |
| UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. | UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation.
Santos N, Rodríguez-Romanos R, Nieto JB, Buño I, Vallejo C, Jiménez-Velasco A, Brunet S, Buces E, López-Jiménez J, González M, Ferrá C, Sampol A, de la Cámara R, Martínez C, Gallardo D, GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH). | 10/1/2016 |
| This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen. | Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
Romero-Lorca A, Novillo A, Gaibar M, Bandrés F, Fernández-Santander A., Free PMC Article | 05/7/2016 |
| miR-376c is inversely linked to UGT2B15 and UGT2B17 expression in high-grade prostate cancer and metastasis.UGT2B15 and UGT2B17 genes are direct targets of miR-376c and thus may influence steroid metabolism during prostate cancer progression. | Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
Margaillan G, Lévesque É, Guillemette C. | 05/7/2016 |
| UGT2B17 deletion polymorphisms are associated with the risk of developing pancreatic cancer in Chinese Han population, especially in the female population. | Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population.
Che X, Yu D, Wu Z, Zhang J, Chen Y, Han Y, Wang C, Qi J. | 03/12/2016 |
| UGT2B17-deletion interacting with p16 (+) may modify effects of smoking on TP53-mutations and may further interact with the disruptive TP53-mutations to raise relapse rates among Japanese patients with head and neck squamous cell carcinomas. | Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
Mafune A, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C, Imai S, Nakashima A, Yokoo T, Wada K, Kojima H, Urashima M., Free PMC Article | 02/6/2016 |